Clinical trial NCT06076122: Salicornia for Neurovascular Health Improve
Official title: Halophyte Plants as a Dietary Supplement to Improve Neurovascular Health
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stroke
Ischemic Stroke
Neurovascular Injury
Brain Ischemia
Keywords: Polyphenol
Salicornia
Brain ischemia
Neuroprotection
Halophytes
Lead sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Sponsor class: OTHER
First posted: 2023-10-10
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Multicentre, randomised, triple-blind, parallel-group, placebo-controlled pilot trial.
Primary purpose: PREVENTION

Brief summary: The purpose of this study is evaluate the effect and safety of the administration of a food supplement based on halophyte plant extracts versus placebo in the neurovascular healthy.

Detailed description: After being informed about the study and giving written informed consent, healthy volunteers (substudy A), patients with transient ischemic attack (TIA) or MINOR stroke (substudy B), patients with cerebral small vessel disease (substudy C) and patients who have suffered a non-disabling stroke and are going to receive carotid angioplasty and stenting (CAS) (substudy D) will be randomized in double-blind manner (participant and investigator) to take a food supplement based on halophyte plant extracts (1 g once a day) or placebo (once a day) for a treatment period of 3 months (substudy A), 11 months (substudy B), 1 year (substudy C) or 7-30 days (substudy D). Participants in substudy A will be twice as likely to be assigned to the experimental treatment as to placebo (2:1 ratio), while those in substudies B, C and D will be equally likely (1:1 ratio).

Eligibility criteria: Substudy A:

* Inclusion Criteria:

  1. Patients ≥18 years old
  2. Possibility of analytical controls at the beginning/end of the study.
  3. Willingness and ability to give informed consent.
* Exclusion Criteria:

  1. Known neurovascular disease.
  2. Other chronic diseases for which the subject is taking medication on a regular basis.
  3. Hyperthyroidism according to the investigator's criteria.
  4. Volunteers taking vitamin or polyphenol-containing nutritional supplements in the 30 days prior to the screening visit (at the investigator's discretion).
  5. Severe illness with life expectancy of less than three months.
  6. Known allergies or intolerance to halophyte plants.
  7. Pregnant or lactating women.
  8. Presence of active neoplastic disease.
  9. Having participated in another clinical trial with medicinal products in the 30 days prior to the screening visit, or intending to do so during their participation in this study.
  10. Habitual consumption of halophyte plants.
  11. Patients who, at the investigator's discretion, are not able to comply with the study protocol.

Substudy B:

* Inclusion criteria:

  1. Patients ≥18 years old.
  2. Patients with typical symptoms lasting less than 24 hours seen at the HUVM classified as TIA or minor stroke (if Diffusion weighted imaging (DWI) positive on magnetic resonance imaging (MRI)) during the last year.
  3. Have a neuroimaging performed at the time of the acute episode that rules out other non-vascular lesions.
  4. Willingness and ability to give informed consent.
* Exclusion criteria:

  1. Patients taking vitamin or polyphenol-containing nutritional supplements in the 30 days prior to the screening visit (at the investigator's discretion).
  2. Having participated in another clinical trial with medicinal products in the 30 days prior to the screening visit, or intending to do so during their participation in this study.
  3. Hyperthyroidism at the investigator's discretion.
  4. Dysphagia that prevents the intake of the study treatment.
  5. Patients dependent for basic activities of daily living (mRS \>3) or with severe disease with life expectancy of less than 12 months.
  6. Known allergies or intolerance to halophyte plants.
  7. Habitual consumption of halophyte plants.
  8. Pregnant or lactating women.
  9. Presence of active neoplastic disease.
  10. Patients who, at the investigator's discretion, are unable to comply with the study protocol.

Substudy C:

* Inclusion criteria:

  1. Patients ≥18 years of age.
  2. Lacunar syndrome with acute ischaemic lesion on neuroimaging of less than 1.5 cm maximum diameter.
  3. Willingness and ability to give informed consent.
* Exclusion criteria:

  1. Patients taking vitamin or polyphenol-containing nutritional supplements in the 30 days prior to the screening visit (at the investigator's discretion).
  2. Hyperthyroidism at the investigator's discretion.
  3. Claustrophobia or morbid obesity (IMT \>40) precluding performance of MRI 3 Tesla.
  4. Patients dependent for basic activities of daily living (mRS \>3) or with severe disease with an expected life expectancy of less than 12 months.
  5. Dysphagia that prevents the intake of the study treatment.
  6. Known allergies or intolerances to halophyte plants.
  7. Pregnant or breastfeeding women.
  8. Presence of active neoplastic disease.
  9. Having participated in another clinical trial with medicinal products in the 30 days prior to the screening visit, or intending to do so during their participation in this study.
  10. Habitual consumption of halophyte plants.
  11. Patients who, at the investigator's discretion, are not able to comply with the study protocol.

Substudy D:

* Inclusion criteria:

  1. Patient with carotid stenosis that warrants treatment in one of the following cases:

     * Symptomatic carotid stenosis \>50% with stroke within 6 months prior to inclusion and not disabling at the time of inclusion.
     * Asymptomatic carotid stenosis \>70% provided some of the following criteria are met:

     I. Presence of silent stroke on neuroimaging.

     II. Stenosis with progression (\>20%).

     III. Soft or ulcerated (unstable) plaque.

     IV. Occlusion of contralateral internal carotid artery (ICA).

     V. Impaired haemodynamic reserve.
  2. Receive carotid angioplasty and stenting (CAS) of said artery within a maximum of one month after inclusion and with a minimum of one week of taking the treatment from inclusion to intervention.
  3. Be able to orally take the dietary supplement/placebo from the event until just prior to the intervention.
  4. Patients ≥18 years.
  5. Willingness and ability to give informed consent.
* Exclusion criteria:

  1. Patients taking vitamin or polyphenol-containing nutritional supplements in the 30 days prior to the screening visit (at the investigator's discretion).
  2. Hyperthyroidism at the investigator's discretion.
  3. Claustrophobia or morbid obesity preventing the performance of MRI 1.5 Tesla.
  4. Severe disease with expected life expectancy of less than one month.
  5. Dysphagia preventing the intake of the study treatment.
  6. Known allergies or intolerance to halophyte plants.
  7. Pregnant or lactating women.
  8. Presence of active neoplastic disease.
  9. Having participated in another clinical trial with medicinal products in the 30 days prior to the screening visit, or intending to do so during their participation in this study.
  10. Habitual consumption of halophyte plants.
  11. Patients who, at the investigator's discretion, are not able to comply with the study protocol.

Primary outcomes:
measure: Incidence of adverse events
timeFrame: Through study completion, up to 1 year.
Secondary outcomes:
measure: Participants with change from baseline in blood cholesterol
timeFrame: Baseline and up to 1 year.
measure: Participants with change from baseline in blood homocysteine
timeFrame: Baseline and up to 1 year.
measure: Participants with change from baseline in blood glycosylated haemoglobin
timeFrame: Baseline and up to 1 year.
measure: Participants with change from baseline in blood Fatty acid-binding protein 2 (FABP2)
timeFrame: Baseline and up to 1 year.
measure: Change from baseline in the degree of cognitive impairment (in substudies B and C)
timeFrame: Baseline, 6 months and 1 year.
measure: Changes in Functional Ambulatory Profile (FAP) (in substudies B and C)
timeFrame: Baseline, 6 months and 1 year.
measure: Efficacy in preventing new major cardiovascular events (in substudies B and C).
timeFrame: Baseline, 6 months and 1 year.
measure: Changes in average systolic blood pressure (in substudy C)
timeFrame: Baseline, 6 months and 1 year.
measure: Changes in average diastolic blood pressure (in substudy C)
timeFrame: Baseline, 6 months and 1 year.
measure: Changes in pulsatility index in middle cerebral artery (MCA) (in substudy C)
timeFrame: Baseline, 6 months and 1 year.
measure: Efficacy in preventing new lesions related to small vessel disease from baseline (in substudy C).
timeFrame: Baseline and 1 year.
measure: Efficacy in preventing new diffusion-weighted imaging (DWI) cerebral lesions from baseline (in substudy D)
timeFrame: Final visit (from day 7 to day 30)
Other outcomes:
Locations:
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena
Study officials:
affiliation: Virgen Macarena (HUVM) and Virgen del Rocío University Hospitals (HUVR) and Institute of Biomedicine of Seville (iBIs)
name: Joan Montaner Villalonga
role: PRINCIPAL_INVESTIGATOR
References: